Shire's Diverse Portfolio Shows Strong 2Q Morningstar.com Sales growth was mostly driven by four of Shire's eight main products: two ADHD drugs (Vyvanse and Intuniv) and two genetic disease therapies (Vpriv and ... Shire's revenue up on rise in rare disease drugs Telegraph.co.uk Shire raises full-year outlook on strong second quarter Pharma Times all 14 news articles »

Shire, the British drugmaker buying Belgium's Movetis , beat second-quarter expectations as its rare disease franchise capitalised on production troubles at United States rival Genzyme. (05/08/2010 09:12:08) Britain's third-largest drug maker, Shire, has revealed a jump in second-quarter revenues as its rare diseases division capitalised on production problems at US competitor, Genzyme.

Shire's revenue up on rise in rare disease drugs Telegraph.co.uk Among the rest of Shire's portfolio, sales of its attention-deficit hyperactivity disorder medicine, Vyvanse, rose 30pc to $148m. ... Shire raises full-year outlook on strong second quarter Pharma Times all 14 news articles »

Shire the acquisitive drugmaker buying Belgium's Movetis beat second-quarter expectations after its rare disease franchise capitalised on production woes at U.S. rival Genzyme .